[Expression of ARA55 mRNA in prostate carcinoma tissues and its significance].
OBJECTIVE
To investigate the expression of ARA55 mRNA in the prostate carcinoma tissues and its clinical significance.


METHODS
Real-time RT-PCR was used to examine the expression of ARA55 mRNA in the samples of the prostate carcinoma tissues from 32 patients.


RESULTS
ARA55 mRNA expressed in different degrees in all the samples. The Ct values were 20.57 +/- 0.20 and 16.33 +/- 0.31 at T1-T2 and T3-T4 stages, 23.13 +/- 0.13 and 17.3 +/- 0.19 for those with Gleason score < or =7 and >7, 24.70 +/- 0.27 and 17.21 +/- 0.34 for those with PSA < or =10 microg/L and >10 microg/L, and 23.82 +/- 0.21 and 16.71 +/- 0.32 for those that responded to endocrinological therapy and those that failed to, respectively. There was a significant difference between the former and the latter.


CONCLUSIONS
ARA55 mRNA expression is significantly correlated with the clinical characteristics of the patient. And ARA55 can be regarded as a prognostic molecular marker for prostate carcinoma as well as a predictor of endocrinological therapeutic effect on the disease.
Yang
Nian-qin
NQ
Department of Urology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200001, China.
Li
Run-sheng
RS
Li
Dong
D
Sha
Jian-jun
JJ
Li
Ping
P
Wang
Yi-xin
YX
D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D060588:LIM Domain Proteins; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome
D047908:Intracellular Signaling Peptides and Proteins; D060588:LIM Domain Proteins; D012333:RNA, Messenger; C490351:TGFB1I1 protein, human